AAAAAA

   
Results: 1-24 |
Results: 24
BILIRUBIN (BIL) AND SN-38 - PHARMACOKINETIC PHARMACODYNAMICS CORRELATION/
Authors: WASSERMAN E MYARA A LOKIEC F RIOFRIO M IMADALOU K BLEUZEN P SANTONI J TRIVIN F HERAIT P MAHJOUBI M ARMAND JP MISSET JL CVITKOVIC E
Citation: E. Wasserman et al., BILIRUBIN (BIL) AND SN-38 - PHARMACOKINETIC PHARMACODYNAMICS CORRELATION/, Annals of oncology, 9, 1998, pp. 220-220
PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN-INDUCED DELAYED-ONSET DIARRHEA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A PROSPECTIVE ASSESSMENT
Authors: SALIBA F HAGIPANTELLI R MISSET JL BASTIAN G VASSAL G BONNAY M HERAIT P COTE C MAHJOUBI M MIGNARD D CVITKOVIC E
Citation: F. Saliba et al., PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN-INDUCED DELAYED-ONSET DIARRHEA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A PROSPECTIVE ASSESSMENT, Journal of clinical oncology, 16(8), 1998, pp. 2745-2751
COMPARISON OF THE PHARMACOKINETICS AND EFFICACY OF IRINOTECAN AFTER ADMINISTRATION BY THE INTRAVENOUS VERSUS INTRAPERITONEAL ROUTE IN MICE
Authors: GUICHARD S CHATELUT E LOCHON I BUGAT R MAHJOUBI M CANAL P
Citation: S. Guichard et al., COMPARISON OF THE PHARMACOKINETICS AND EFFICACY OF IRINOTECAN AFTER ADMINISTRATION BY THE INTRAVENOUS VERSUS INTRAPERITONEAL ROUTE IN MICE, Cancer chemotherapy and pharmacology, 42(2), 1998, pp. 165-170
CONSISTENT SAFETY AND EFFICACY RESULTS IN 2 STUDY POPULATIONS TREATEDWITH IRINOTECAN (CPT-11) FOR METASTATIC COLORECTAL-CANCER (MCRC) RESISTANT TO 5-FU
Authors: GUIMBAUD R BUGAT R VANCUTSEM E MIGNARD D MAHJOUBI M CANAL P BLANC C
Citation: R. Guimbaud et al., CONSISTENT SAFETY AND EFFICACY RESULTS IN 2 STUDY POPULATIONS TREATEDWITH IRINOTECAN (CPT-11) FOR METASTATIC COLORECTAL-CANCER (MCRC) RESISTANT TO 5-FU, European journal of cancer, 33, 1997, pp. 736-736
SEVERE CPT-11 TOXICITY IN PATIENTS WITH GILBERTS-SYNDROME - 2 CASE-REPORTS
Authors: WASSERMAN E MYARA A LOKIEC F GOLDWASSER F TRIVIN F MAHJOUBI M MISSET JL CVITKOVIC E
Citation: E. Wasserman et al., SEVERE CPT-11 TOXICITY IN PATIENTS WITH GILBERTS-SYNDROME - 2 CASE-REPORTS, Annals of oncology, 8(10), 1997, pp. 1049-1051
HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY
Authors: MERROUCHE Y EXTRA JM ABIGERGES D BUGAT R CATIMEL G SUC E MARTY M HERAIT P MAHJOUBI M ARMAND JP
Citation: Y. Merrouche et al., HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY, Journal of clinical oncology, 15(3), 1997, pp. 1080-1086
PHASE-II STUDY OF IRINOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER IN CHEMOTHERAPY-NAIVE PATIENTS AND PATIENTS PRETREATED WITH FLUOROURACIL-BASED CHEMOTHERAPY
Authors: ROUGIER P BUGAT R DOUILLARD JY CULINE S SUC E BRUNET P BECOUARN Y YCHOU M MARTY M EXTRA JM BONNETERRE J ADENIS A SEITZ JF GANEM G NAMER M CONROY T NEGRIER S MERROUCHE Y BURKI F MOUSSEAU M HERAIT P MAHJOUBI M
Citation: P. Rougier et al., PHASE-II STUDY OF IRINOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER IN CHEMOTHERAPY-NAIVE PATIENTS AND PATIENTS PRETREATED WITH FLUOROURACIL-BASED CHEMOTHERAPY, Journal of clinical oncology, 15(1), 1997, pp. 251-260
RAPID TUMOR LYSIS SYNDROME IN A METASTATIC COLORECTAL-CANCER INCREASED BY TREATMENT WITH IRINOTECAN (CPT-11)
Authors: BOISSEAU M BUGAT R MAHJOUBI M
Citation: M. Boisseau et al., RAPID TUMOR LYSIS SYNDROME IN A METASTATIC COLORECTAL-CANCER INCREASED BY TREATMENT WITH IRINOTECAN (CPT-11), European journal of cancer, 32A(4), 1996, pp. 737-738
CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER
Authors: ARMAND JP DUCREUX M MAHJOUBI M ABIGERGES D BUGAT R CHABOT G HERAIT P DEFORNI M ROUGIER P
Citation: Jp. Armand et al., CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER, European journal of cancer, 31A(7-8), 1995, pp. 1283-1287
CPT-11 (IRINOTECAN) IN PRETREATED SMALL-CELL LUNG-CANCER (SCLC) - A PHASE-II STUDY IN PATIENTS PROGRESSING AFTER A FIRST RESPONSE (PRELIMINARY-RESULTS)
Authors: PUJOL JL LECHEVALIER T DOUILLARD JY RIVIERE A CHOMY P MONIER A MAHJOUBI M
Citation: Jl. Pujol et al., CPT-11 (IRINOTECAN) IN PRETREATED SMALL-CELL LUNG-CANCER (SCLC) - A PHASE-II STUDY IN PATIENTS PROGRESSING AFTER A FIRST RESPONSE (PRELIMINARY-RESULTS), European journal of cancer, 31A, 1995, pp. 92-92
A PHASE-II STUDY OF CPT-11 (IRINOTECAN) IN REFRACTORY TO 5-FU COLORECTAL-CANCER (CRC) WITH, PREVENTIVE TREATMENT OF DELAYED DIARRHEA BY ACETORPHAN
Authors: EXTRA JM ROUGIER P YCHOU M DOUILLARD JY ADENIS A MOUSSEAU M ASSADOURIAN S MAHJOUBI M MARTY M
Citation: Jm. Extra et al., A PHASE-II STUDY OF CPT-11 (IRINOTECAN) IN REFRACTORY TO 5-FU COLORECTAL-CANCER (CRC) WITH, PREVENTIVE TREATMENT OF DELAYED DIARRHEA BY ACETORPHAN, European journal of cancer, 31A, 1995, pp. 727-727
PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN (CPT-11) INDUCED DELAYED-ONSET DIARRHEA (DD) - A PROSPECTIVE ASSESSMENT
Authors: MISSET JL SALIBA F GIACCHETTI S BRAIN E VASSAL G BONNAY M BASTIAN G COTE C MAHJOUBI M HERAIT P HAGIPANTELLI R CVITKOVIC E
Citation: Jl. Misset et al., PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN (CPT-11) INDUCED DELAYED-ONSET DIARRHEA (DD) - A PROSPECTIVE ASSESSMENT, European journal of cancer, 31A, 1995, pp. 742-742
A PHASE-II STUDY OF CPT-11 (IRINOTECAN) IN REFRACTORY TO 5FU COLORECTAL-CANCER WITH CURATIVE TREATMENT OF DELAYED DIARRHEA BY ACETORPHAN
Authors: MERROUCHE Y BUGAT R BRUNET R SEITZ JF CONROY T FABRE V NAMER M PIOLAT V MAHJOUBI M DROZ JP
Citation: Y. Merrouche et al., A PHASE-II STUDY OF CPT-11 (IRINOTECAN) IN REFRACTORY TO 5FU COLORECTAL-CANCER WITH CURATIVE TREATMENT OF DELAYED DIARRHEA BY ACETORPHAN, European journal of cancer, 31A, 1995, pp. 759-759
A PHASE-I STUDY OF CONCOMITANT CPT-11 (C) AND 5FU (F) COMBINATION - PRELIMINARY-RESULTS
Authors: RIXE O BENHAMMOUDA A FARABOS C BOREL C PETIT T AUCLERC G COEFFIC D BASTIAN G GROSSIN F PARAISO D GRAPIN JP NIZRI D WEIL M BISMUTH H MAHJOUBI M KHAYAT D
Citation: O. Rixe et al., A PHASE-I STUDY OF CONCOMITANT CPT-11 (C) AND 5FU (F) COMBINATION - PRELIMINARY-RESULTS, European journal of cancer, 31A, 1995, pp. 955-955
PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDDAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: CATIMEL G CHABOT GG GUASTALLA JP DUMORTIER A COTE C ENGEL C GOUYETTE A MATHIEUBOUE A MAHJOUBI M CLAVEL M
Citation: G. Catimel et al., PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDDAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS, Annals of oncology, 6(2), 1995, pp. 133-140
EFFICACY OF COMBINED 5-FLUOROURACIL AND CISPLATINUM IN ADVANCED GASTRIC CARCINOMAS - A PHASE-II TRIAL WITH PROGNOSTIC FACTOR-ANALYSIS
Authors: ROUGIER P DUCREUX M MAHJOUBI M PIGNON JP BELLEFQIH S OLIVEIRA J BOGNEL C LASSER P YCHOU M ELIAS D CVITKOVIC E ARMAND JP DROZ JP
Citation: P. Rougier et al., EFFICACY OF COMBINED 5-FLUOROURACIL AND CISPLATINUM IN ADVANCED GASTRIC CARCINOMAS - A PHASE-II TRIAL WITH PROGNOSTIC FACTOR-ANALYSIS, European journal of cancer, 30A(9), 1994, pp. 1263-1269
NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC-CARCINOMA - A PHASE-II TRIAL WITH COMBINED CONTINUOUS INTRAVENOUS 5-FLUOROURACIL AND BOLUS CISPLATINUM
Authors: ROUGIER P MAHJOUBI M LASSER P DUCREUX M OLIVEIRA J YCHOU M PIGNON JP ELIAS D BELLEFQIH S BOGNEL C LUSINCHI A CVITKOVIC E DROZ JP
Citation: P. Rougier et al., NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC-CARCINOMA - A PHASE-II TRIAL WITH COMBINED CONTINUOUS INTRAVENOUS 5-FLUOROURACIL AND BOLUS CISPLATINUM, European journal of cancer, 30A(9), 1994, pp. 1269-1275
PREOPERATIVE CHEMOTHERAPY OF LOCALLY ADVANCED GASTRIC-CANCER
Authors: ROUGIER P LASSER P DUCREUX M MAHJOUBI M BOGNEL C ELIAS D
Citation: P. Rougier et al., PREOPERATIVE CHEMOTHERAPY OF LOCALLY ADVANCED GASTRIC-CANCER, Annals of oncology, 5, 1994, pp. 190000059-190000068
PHASE-II TRIAL OF PIRARUBICIN IN THE TREATMENT OF ADVANCED PANCREATIC-CANCER
Authors: MAHJOUBI M ROUGIER P OLIVIERA J HERAIT P TIGAUD JM DROZ JP
Citation: M. Mahjoubi et al., PHASE-II TRIAL OF PIRARUBICIN IN THE TREATMENT OF ADVANCED PANCREATIC-CANCER, Cancer investigation, 12(4), 1994, pp. 403-405
PHASE-I STUDY OF RETELLIPTINE DIHYDROCHLORIDE (SR-95325-B) USING A SINGLE 2-HOUR INTRAVENOUS-INFUSION SCHEDULE
Authors: KATTAN J DURAND M DROZ JP MAHJOUBI M MARINO JP AZAB M
Citation: J. Kattan et al., PHASE-I STUDY OF RETELLIPTINE DIHYDROCHLORIDE (SR-95325-B) USING A SINGLE 2-HOUR INTRAVENOUS-INFUSION SCHEDULE, American journal of clinical oncology, 17(3), 1994, pp. 242-245
POTENTIOMETRIC AND SPECTROPHOTOMETRIC STUDIES OF IRON (III), INTERACTION WITH CALIX[6]ARENE P-SULFONIC ACID
Authors: SCHARFF JP MAHJOUBI M PERRIN R
Citation: Jp. Scharff et al., POTENTIOMETRIC AND SPECTROPHOTOMETRIC STUDIES OF IRON (III), INTERACTION WITH CALIX[6]ARENE P-SULFONIC ACID, New journal of chemistry, 17(12), 1993, pp. 793-796
HIGH FAILURE RATE OF CARBOPLATIN ETOPOSIDE COMBINATION IN GOOD RISK NONSEMINOMATOUS GERM-CELL TUMORS
Authors: KATTAN J MAHJOUBI M DROZ JP KRAMAR A CULINE S BOUTANLAROZE A CHAZARD M
Citation: J. Kattan et al., HIGH FAILURE RATE OF CARBOPLATIN ETOPOSIDE COMBINATION IN GOOD RISK NONSEMINOMATOUS GERM-CELL TUMORS, European journal of cancer, 29A(11), 1993, pp. 1504-1509
PHASE-II STUDY OF CISPLATIN AND 120-HOUR CONTINUOUS-INFUSION OF 5-FLUOROURACIL IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA
Authors: ROUGIER P ZARBA JJ DUCREUX M BASILE M PIGNON JP MAHJOUBI M BENAHMED M DROZ JP CVITKOVIC E ARMAND JP
Citation: P. Rougier et al., PHASE-II STUDY OF CISPLATIN AND 120-HOUR CONTINUOUS-INFUSION OF 5-FLUOROURACIL IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA, Annals of oncology, 4(4), 1993, pp. 333-336
PHASE-II TRIAL OF LY-186641 IN ADVANCED RENAL-CANCER
Authors: MAHJOUBI M KATTAN J BONNAY M SCHMITT H DROZ JP
Citation: M. Mahjoubi et al., PHASE-II TRIAL OF LY-186641 IN ADVANCED RENAL-CANCER, Investigational new drugs, 11(4), 1993, pp. 323-328
Risultati: 1-24 |